NASDAQ:BOLD Boundless Bio Q3 2025 Earnings Results & Report $2.43 -0.12 (-4.71%) Closing price 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Boundless Bio missed analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$0.62 versus the -$0.53 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call7:00 AM ET Boundless Bio EPS ResultsActual EPS-$0.62Consensus EPS -$0.53Beat/MissMissed by -$0.09One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersBoundless Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Boundless Bio Q3 2025 Earnings FAQ Did Boundless Bio beat earnings estimates for Q3 2025? Boundless Bio (NASDAQ:BOLD) reported earnings of -$0.62 per share for Q3 2025, missing the consensus estimate of -$0.53. The report was announced on Wednesday, November 5, 2025. Boundless Bio Earnings HeadlinesSerapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin DeficiencySeptember 15, 2026 | globenewswire.comCallio Therapeutics Appoints Zachary Hornby as Chief Executive OfficerSeptember 9, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersJuly 2, 2026 | globenewswire.comBoundless Bio to merge with Serapha Bio in reverse merger; shares surgeJune 23, 2026 | msn.comBOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryJune 23, 2026 | finance.yahoo.comSee More Boundless Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email. Email Address About Boundless BioBoundless Bio (NASDAQ:BOLD) is a clinical-stage oncology biotechnology company focused on developing medicines for cancers driven by extrachromosomal DNA (ecDNA). These circular DNA structures can amplify cancer-causing genes and contribute to tumor growth, treatment resistance and disease progression. The company’s approach is designed to identify and selectively target vulnerabilities created by ecDNA and oncogene amplification. Boundless Bio is advancing a pipeline of ecDNA-directed therapeutic candidates, including small-molecule programs intended to interfere with the formation, maintenance or activity of ecDNA-driven oncogenes. Its research and development efforts are focused on precision oncology, with the goal of developing treatments for patients whose tumors contain specific genomic alterations or ecDNA-related features. Founded in 2018 and headquartered in San Diego, California, Boundless Bio conducts drug discovery and clinical development activities for oncology applications. The company became publicly traded on the Nasdaq under the symbol BOLD in 2024. Boundless Bio is led by President and Chief Executive Officer Zachary M. Hornby.View Boundless Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
